Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction: Findings From the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 Trial

BACKGROUND—: Vorapaxar reduces cardiovascular death, myocardial infarction (MI), or stroke in patients with previous MI while increasing bleeding. Patients with diabetes mellitus (DM) are at high risk of recurrent thrombotic events despite standard therapy and may derive particular benefit from anti...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Circulation
Main Authors: Cavender, Matthew A., Scirica, Benjamin M., Bonaca, Marc P., Angiolillo, Dominick J., Dalby, Anthony J., Dellborg, Mikael, Morais, Joao, Murphy, Sabina A., Ophuis, Ton Oude, Tendera, Michal, Braunwald, Eugene, Morrow, David A.
Format: Artigo
Jezik:Inglês
Izdano: Lippincott Williams & Wilkins 2015
Teme:
Original Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4365950/
https://ncbi.nlm.nih.gov/pubmed/25681464
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.114.013774
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki